Aumolertinib in non-small cell lung cancer with uncommon EGFR exon 19 deletions: a real-world dual-center study
A lung cancer drug works consistently well for patients with a specific genetic variant, offering clearer guidance when detailed genetic testing isn't available.
In 118 patients with uncommon EGFR E19del NSCLC, aumolertinib demonstrated consistent cross-subtype efficacy (mPFS 15.9 months) compared to osimertinib's subtype-dependent performance, supported by molecular docking data showing stronger L747-deletion binding. The findings support molecular subtype-guided TKI selection and aumolertinib as a preferred option in settings lacking comprehensive molecular stratification.
What the study was
- Study design
- Dual-center retrospective cohort study with NGS molecular profiling
- Population
- Advanced/recurrent NSCLC patients with uncommon EGFR exon 19 deletions (excluding E746_A750del), China
- Sample size
- 118
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- BMC Cancer
Why it surfaced
Real-world dual-center study N=118 with NGS profiling and molecular modeling; directly actionable for NSCLC precision TKI selection; aumolertinib consistently superior across uncommon EGFR E19del subtypes.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.